Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03571594
Other study ID # ONO-5788-01
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date June 7, 2018
Est. completion date May 16, 2019

Study information

Verified date June 2019
Source Ono Pharmaceutical Co. Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-5788 in healthy adult volunteers. This study will be conducted in 4 parts: a single-ascending dose part, a multiple-ascending dose part, an elderly part and a proof of principle part.


Description:

This single centre study will be comprised of 4 parts, Part A (SAD; up to 7 cohorts, 8 subjects per cohort and including an assessment of food effect), a multiple-dose part (up to 4 doses, 10 subjects per cohort); an elderly cohort (8 subjects per gender) and a proof of principle part.

The single ascending dose part (Part A) comprises of increasing doses of an oral solution or capsule, with an investigation of the potential for food effects.

The multiple ascending dose part (Part B, MAD; 14 days dosing) will be initiated after the PK and safety data are available from the single ascending dose part. Subjects in Part B will have ultrasound scans of the gallbladder during the study and at screening a HIDA scan will be performed. An evaluation of the PK in the elderly and any potential gender differences will also be evaluated in Part C. Subjects in Part C will have an ultrasound of the gallbladder at screening.

Part D will be a proof of principle evaluation where the effects of ONO-5788 to inhibit the GHRH and arginine-stimulated GH release will be evaluated. Octreotide acetate is a reference arm in this part of the study.


Recruitment information / eligibility

Status Terminated
Enrollment 76
Est. completion date May 16, 2019
Est. primary completion date May 16, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Healthy, adult, male and female (women of non-child bearing potential, surgically sterile) volunteers, 18-55 years of age, inclusive, at screening (Parts A & B only).

- Healthy, adult, males and female (women of non-child bearing potential), =65 years of age at screening (Part C only).

- Healthy, adult, male, 18-40 years of age, inclusive, at screening (Part D only).

- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECG abnormalities (All Parts).

- Body mass index (BMI) of =18.5 to =30 kg/m2 at screening (Parts A, B & C).

- Body mass index (BMI) of =18.5 to <25 kg/m2 at screening (Part D only).

Exclusion Criteria:

- History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

- History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.

- History or presence of hypersensitivity or idiosyncratic reaction to the study drugs,excipients or related compounds.

- History or presence of:

1. Gallstones, cholangitis, and/or cholecystitis or clinically significant findings on gallbladder ultrasound as determined by the Principal Investigator;

2. Pancreatitis;

3. Hypothyroidism;

4. Known diabetes mellitus type 1 or type 2;

5. Hypocalcaemia or hypokalemia;

6. Hypoglycemia or hyperglycemia or fasting blood glucose outside normal local range;

7. Thrombocytopenia or other clinically significant hematologic abnormalities;

8. Inflammatory bowel disease, irritable bowel syndrome, or abdominal surgery;

9. Known vitamin B12 deficiency.

10. Abnormal gallbladder ejection fraction on hepatobiliary iminodiacetic acid (HIDA) scan at screening (Part B only)

- Positive urine drug, alcohol or cotinine results at screening or check in.

- Clinically significant serum electrolyte (sodium, potassium, chloride, bicarbonate) abnormalities at screening or each check-in, in the estimation and clinical judgment of the PI or designee.

- Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).

- Seated blood pressure is less than 90/40 millimeter of mercury (mmHg) or greater than 140/90 mmHg (160/95 mmHg for Part C) at screening.

- Has engaged in strenuous physical exercise in the 48 hours prior first dosing or intends to undergo strenuous physical exercise at any time throughout the study.

- Donation of blood or significant blood loss within 56 days prior to the first dosing.

- Plasma donation within 7 days prior to the first dosing.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ONO-5788
Investigational drug
ONO-5788 Placebo
Placebo Comparator
Octreotide
Active Comparator in Part D

Locations

Country Name City State
United States Celerion Tempe Arizona

Sponsors (1)

Lead Sponsor Collaborator
Ono Pharmaceutical Co. Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with treatment emergent adverse events by severity An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possible causal relationship. Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
Primary Number of participants with serious adverse events (SAEs) An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged hospitalization, life-threatening experience or persistent disability. Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
Primary Number of participants with clinically significant changes in vital signs Number of participants with clinically significant changes in vital signs including pulse/heart rate, respiratory rate, and blood pressure will be reported. Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
Primary Number of participants with ECG abnormalities Number of participants with ECG abnormalities will be reported Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
Primary Number of participants with clinical laboratory abnormalities Number of participants with clinical laboratory abnormalities will be reported Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
Primary Number of participants with clinically significant change in ultrasound of gallbladder Number of participants with clinically significant change in ultrasound of gallbladder will be reported Part B - up to day 21
Secondary Pharmacokinetics (AUC) Assessment of the plasma area under the curve of ONO-5788 and metabolites (Parts A, B and C only) Day 1 through Day 14
Secondary Pharmacokinetics (AUC) - food effect Effect of food on the plasma area under the curve of ONO-5788 and metabolites (Parts A only) Day 1
Secondary Pharmacokinetics (Cmax) Assessment of the maximum observed plasma concentration of ONO-5788, metabolites (Parts A, B, C & D) and octreotide (Part D only) Day 1 through Day 14
Secondary Pharmacokinetics (Cmax) - food effect Effect of food on the maximum observed plasma concentration of ONO-5788, and metabolites (Part A only) Day 1
Secondary Pharmacokinetics (Tmax) Assessment of the time to reach Cmax for ONO-5788, metabolites (Parts A, B, C & D) and octreotide (Part D only) Day 1 through Day 14
Secondary Pharmacokinetics (Tmax) - food effect Effect of food on the time to reach Cmax for ONO-5788, metabolites (Part A only) Day 1 through Day 14
Secondary Pharmacokinetics (Ctrough) Assessment of trough levels for ONO-5788 and metabolites immediately before dosing (Part B only) Day 1 through Day 14
Secondary Pharmacokinetics (T1/2) Assessment of the elimination half-life of ONO-5788 and metabolites (Parts A, B and C only) Day 1 through Day 14
Secondary Pharmacokinetics (T1/2) - food effect Effect of food on the elimination half-life of ONO-5788 and metabolites (metabolite) (Part A only) Day 1
Secondary Pharmacokinetics (CL/F) Assessment of the apparent clearance rate of ONO-5788 (Parts A & C) Day 1
Secondary Pharmacokinetics (CL/F) - food effect Effect of food on the apparent clearance rate of ONO-5788 (Part A only) Day 1
Secondary Pharmacokinetics (Cave) Average concentration of ONO-5788/metabolites/Octreotide (Part D only) Day 1
Secondary Pharmacodynamics (IGF-1) Assessment of the effects of ONO-5788 on IGF-1 levels (Part B only) Day 1 through Day 21
Secondary Pharmacodynamics (Growth Hormone) Assessment of the effects of ONO-5788 on GH levels (Part B) Day 1 through Day 21
Secondary Pharmacodynamics (Growth Hormone) Assessment of the effects of ONO-5788 on GHRH & arginine stimulated GH levels (Part D) Day 1
Secondary Pharmacodynamics (IGFBP3) Assessment of the effects of ONO-5788 on IGFBP3 levels (Part B only) Day 1 through Day 21
See also
  Status Clinical Trial Phase
Recruiting NCT06344650 - Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
Active, not recruiting NCT02092129 - Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. N/A
Completed NCT02012127 - Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
Active, not recruiting NCT01265121 - Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism. N/A
Terminated NCT00765323 - Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly Phase 3
Completed NCT00531908 - Physiopathology of Sodium Retention in Acromegaly N/A
Completed NCT00500227 - Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
Completed NCT01278342 - Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Phase 4
Active, not recruiting NCT01809808 - A Prospective Study of Outcome After Therapy for Acromegaly
Completed NCT00145405 - Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Phase 4
Completed NCT00210457 - Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Phase 3
Recruiting NCT05401084 - Diet in the Management of Acromegaly N/A
Recruiting NCT00005100 - Measurement of Outcome of Surgical Treatment in Patients With Acromegaly N/A
Completed NCT00521300 - Preoperative Octreotide Treatment of Acromegaly Phase 4
Completed NCT03548415 - Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands Phase 2
Not yet recruiting NCT04066569 - Reproducibility and Utility of OGTT in Acromegaly N/A
Not yet recruiting NCT05298891 - Hypoproteic Diet in Acromegaly N/A
Recruiting NCT04520646 - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy N/A
Not yet recruiting NCT04529356 - The TMS Treatment for Postoperative Headache in GH Tumor N/A
Active, not recruiting NCT03252353 - Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Phase 3